CDK1 drives SOX9-mediated chemotherapeutic resistance in gastric cancer
This study elucidates the epigenetic and transcriptional mechanisms driving the CDK1-SOX9-BCL-xL axis in gastric cancer chemoresistance. Pharmacological inhibition of CDK1 effectively disrupts this axis, restoring cisplatin sensitivity and suppressing tumor growth in gastric cancer models. The observed synergy between dinaciclib and cisplatin underscores a promising therapeutic strategy to overcome chemoresistance in gastric cancer.
Authors
- Dunfa Peng (ORCID: https://orcid.org/0000-0002-2182-7221)
- Alexander Zaika (ORCID: https://orcid.org/0000-0001-6760-2020)
- Marwah M. Al‐Mathkour
- Oliver G. McDonald (ORCID: https://orcid.org/0000-0002-6602-7535)
- Shoumin Zhu (ORCID: https://orcid.org/0000-0001-6907-2916)
- Yan Guo (ORCID: https://orcid.org/0000-0001-5252-3960)
- Julio Poveda (ORCID: https://orcid.org/0009-0003-3075-0849)
- Shria Kumar (ORCID: https://orcid.org/0000-0001-9745-2676)
- Zhibin Chen (ORCID: https://orcid.org/0009-0007-0046-1682)
- Mohammed Soutto (ORCID: https://orcid.org/0000-0002-5597-4588)
- Zheng Chen (ORCID: https://orcid.org/0000-0002-6367-7647)
- Heng Lu (ORCID: https://orcid.org/0000-0001-9775-7824)
- Silvia Giordano
- Long‐Long Cao
- Wael El-Rifai
Institutions
- Fujian Medical University (CN)
- University of Miami (US)
- Candiolo Cancer Institute (IT)
- Sylvester Comprehensive Cancer Center (US)
- Union Hospital (CN)
- Miami VA Healthcare System (US)
Publication Details
- Journal
- Journal of Experimental & Clinical Cancer Research
- Published
- 2025-10-08
- DOI
- https://doi.org/10.1186/s13046-025-03523-3
- Primary Topic
- Cancer-related gene regulation
- Type
- article
- Field-Weighted Citation Impact
- 0.00